Tilray Shares Surge on Regulatory Speculation

A wave of optimism is sweeping through the U.S. cannabis sector, propelling shares of Tilray significantly higher. The stock extended its gains on Wednesday, building on a dramatic 27.5% surge the previous day. This rally is fueled entirely by market speculation that former President Donald Trump may issue an executive order to reclassify marijuana, an event traders have playfully dubbed “Weednesday.”

Volume and Technicals Reflect Frenzied Buying

Investor enthusiasm is unmistakable in the trading data. On Tuesday, more than 46 million shares changed hands—a volume exceeding five times the three-month average. Both institutional and retail investors are participating in the move. Market technicians view the stock’s ability to hold above the $13 level as a sign of underlying strength.

The company’s share structure has recently changed, following a 1-for-10 reverse stock split executed on December 1, 2025, to maintain compliance with Nasdaq listing requirements. Despite this adjustment and the recent price advance, analysts see further potential; the average price target sits near $16.17, suggesting over 15% upside from current levels.

Should investors sell immediately? Or is it worth buying Tilray?

The Core Driver: A Potential Regulatory Shift

At the heart of the buying frenzy is the prospect of a historic regulatory change. Reports suggest the administration is considering moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. Such a reclassification would have profound implications: it would eliminate the burdensome 280E tax provision, which currently prevents cannabis companies from deducting standard business expenses, and would significantly improve the industry’s access to banking services.

While Tilray continues its operational expansion, including the recent launch of new Redecan brand vape products in Canada, its stock price is currently being dictated by U.S. political developments. The company often acts as a bellwether for the entire sector, with its momentum lifting competitors like Canopy Growth as well.

Outlook Hinges on Political Follow-Through

The sustainability of the rally now depends on whether the political rumors materialize into action. Should the White House or the Drug Enforcement Administration (DEA) fail to provide concrete timelines or orders, the market could see rapid profit-taking. For a longer-term trend to establish, the shares will need to defend their support above the 200-day moving average leading into the next earnings season in January 2026. Until then, volatility is expected to remain exceptionally high.